EGFR and lung cancer: In conclusion, our data demonstrate the clinical potential of beta-arrestin-1 as a differential diagnostic marker in lung cancer and highlight the additional utility that it can bear as a non-invasive biomarker for the diagnosis and for prediction of response to EGFR inhibitor therapy in lung cancer.